About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Ins2
insulin II
MGI:96573
89 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Bdkrb2tm1Jfh/Bdkrb2tm1Jfh
Ins2Akita/Ins2+
B6.Cg-Ins2Akita Bdkrb2tm1Jfh 		abnormal intestinal epithelium morphology J:108948
abnormal Leydig cell morphology J:108948
abnormal mitochondrial chromosome morphology J:108948
abnormal seminiferous tubule morphology J:108948
abnormal spermatic cord morphology J:108948
abnormal spermatogonia morphology J:108948
alopecia J:108948
decreased bone mineral density J:108948
decreased subcutaneous adipose tissue amount J:108948
kyphosis J:108948
premature death J:108948
Cebpbtm1.1Maka/Cebpbtm1.1Maka
Ins2Akita/Ins2Akita
Tg(Ins2-cre)23Herr/0
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NSlc * CBA/J 		abnormal pancreatic beta cell mass J:156725
abnormal pancreatic islet cell apoptosis J:156725
decreased circulating insulin level J:156725
decreased insulin secretion J:156725
increased circulating glucose level J:156725
Dbm1A/J/Dbm1A/J
Ins2Akita/Ins2+
involves: A/J * C57BL/6J * C57BL/6NSlc 		increased body weight J:112869
increased circulating glucose level J:112869
increased circulating insulin level J:112869
Dbm3C57BL/6J/?
Ins2Akita/Ins2+
involves: A/J * C57BL/6J * C57BL/6NSlc 		abnormal circulating glucose level J:112869
Dbm4C57BL/6J/?
Ins2Akita/Ins2+
involves: A/J * C57BL/6J * C57BL/6NSlc 		abnormal circulating glucose level J:112869
Ero1bGt(P077G11)Wrst/Ero1b+
Ins2Akita/Ins2+
involves: 129S2/SvPas * C57BL/6NSlc 		decreased insulin secretion J:158805
impaired glucose tolerance J:158805
increased circulating glucose level J:158805
small pancreatic islets J:158805
Gasttm1(INS)Ez/Gast+
Ins2Akita/Ins2+
involves: 129S4/SvJae * C57BL/6NSlc 		abnormal circulating glucose level J:99270
normal mortality/aging J:99270
H2g7/H2g7
Ins2tm1Jja/Ins2tm1Jja
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraBDC12-4.1)10Jos/0
Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD 		increased circulating glucose level J:111874
increased susceptibility to autoimmune diabetes J:111874
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1.1Mnt/Ins2tm1.1Mnt
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N 		postnatal lethality, complete penetrance J:152798
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2+
involves: 129S2/SvPas * C57BL/6 		increased pancreatic alpha cell mass J:106827
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2tm1Jja
involves: 129S2/SvPas 		abnormal glucose homeostasis J:40377, J:77595
acidosis J:40377
decreased body size J:40377
embryonic growth retardation J:40377
enlarged liver J:40377
enlarged pancreatic islets J:40377
hepatic steatosis J:40377
increased circulating triglyceride level J:40377
increased pancreatic beta cell number J:77595
increased urine glucose level J:40377
postnatal lethality, complete penetrance J:40377
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2tm1Jja
involves: 129S2/SvPas * C57BL/6 		decreased birth weight J:106827
decreased fetal weight J:106827
decreased pancreatic islet cell apoptosis J:106827
enlarged pancreatic islets J:106827
increased pancreatic alpha cell mass J:106827
increased pancreatic alpha cell proliferation J:106827
increased pancreatic beta cell mass J:106827
increased pancreatic beta cell proliferation J:106827
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2tm1Jja
Tg(Ins2*Y16A)1Ell/0
NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)1Ell 		decreased susceptibility to autoimmune diabetes J:98583
increased circulating glucose level J:98583
salivary gland inflammation J:98583
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Jja/Ins2tm1Jja
Tg(Ins2*Y16A)3Ell/0
NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)3Ell 		decreased anti-insulin autoantibody level J:98583
decreased susceptibility to autoimmune diabetes J:98583
salivary gland inflammation J:98583
Ins1tm1Jja/Ins1tm1Jja
Ins2tm1Mnt/Ins2tm1Mnt
Tg(Aire-cre)1Mnt/0
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N 		abnormal circulating insulin level J:152798
abnormal immune system physiology J:152798
abnormal interferon-gamma secretion J:152798
abnormal pancreatic beta cell physiology J:152798
abnormal T cell physiology J:152798
decreased pancreatic beta cell number J:152798
hyperglycemia J:152798
increased anti-insulin autoantibody level J:152798
increased circulating glucose level J:152798
pancreas inflammation J:152798
Ins2Akita/Ins2+
Prf1tm1Sdz/Prf1tm1Sdz
Rag1tm1Mom/Rag1tm1Mom
NOD.Cg-Rag1tm1Mom Ins2Akita Prf1tm1Sdz 		abnormal glucose homeostasis J:138005
abnormal pancreatic islet morphology J:138005
absent mature B cells J:138005
absent T cells J:138005
normal homeostasis/metabolism phenotype J:138005
hyperglycemia J:138005
increased erythrocyte cell number J:138005
increased granulocyte number J:138005
increased macrophage cell number J:138005
increased monocyte cell number J:138005
Ins2Akita/Ins2+
Rnf213tm1.1Akoi/Rnf213tm1.1Akoi
involves: C57BL/6N * C57BL/6NSlc 		abnormal pancreatic islet morphology J:200802
decreased body weight J:200802
decreased circulating leptin level J:200802
decreased insulin secretion J:200802
decreased pancreatic beta cell number J:200802
normal homeostasis/metabolism phenotype J:200802
impaired glucose tolerance J:200802
increased circulating glucose level J:200802
increased food intake J:200802
Ins2Akita/Ins2Akita
Itga1tm1Gdnr/Itga1tm1Gdnr
C.Cg-Ins2Akita Itga1tm1Gdnr 		abnormal glomerular capillary morphology J:198186
abnormal glomerular mesangium morphology J:198186
abnormal kidney interstitium morphology J:198186
albuminuria J:198186
decreased body weight J:198186
expanded mesangial matrix J:198186
glomerulosclerosis J:198186
hyperglycemia J:198186
increased renal glomerular filtration rate J:198186
increased renal glomerulus basement membrane thickness J:198186
mesangiolysis J:198186
premature death J:198186
renal glomerular protein deposits J:198186
Ins2Akita/Ins2Akita
Jazf1tm1c(EUCOMM)Wtsi/Jazf1tm1c(EUCOMM)Wtsi
Tg(Ins2-cre)23Herr/0
involves: 129S4/SvJaeSor * C57BL/6N * C57BL/6NSlc * CBA/J 		abnormal glucose homeostasis J:303318
decreased pancreatic beta cell mass J:303318
decreased pancreatic beta cell proliferation J:303318
normal growth/size/body region phenotype J:303318
increased circulating glucose level J:303318
increased pancreatic beta cell apoptosis J:303318
Ins2Akita/Ins2Akita
Ldlrtm1Her/Ldlrtm1Her
B6.Cg-Ins2Akita Ldlrtm1Her 		decreased body weight J:174983
decreased circulating insulin level J:174983
hyperglycemia J:174983
impaired glucose tolerance J:174983
increased circulating cholesterol level J:174983
increased circulating HDL cholesterol level J:174983
increased circulating LDL cholesterol level J:174983
increased circulating triglyceride level J:174983
increased circulating VLDL cholesterol level J:174983
increased susceptibility to atherosclerosis J:174983
premature death J:174983
Ins2Akita/Ins2Akita
Prf1tm1Sdz/Prf1tm1Sdz
Rag1tm1Mom/Rag1tm1Mom
NOD.Cg-Rag1tm1Mom Ins2Akita Prf1tm1Sdz 		postnatal lethality, complete penetrance J:138005
Ins2Akita/Ins2Akita
Rpl13atm1.1Jesc/Rpl13atm1.1Jesc
FVB.Cg-Rpl13atm1.1Jesc Ins2Akita 		abnormal circulating glucose level J:237822
Ins2tm1Delt/Ins2+
involves: 129S2/SvPas * Black Swiss 		absent pancreatic beta cells J:94589
decreased pancreatic alpha cell number J:94589
dehydration J:94589
hepatic steatosis J:94589
increased circulating ketone body level J:94589
increased urine glucose level J:94589
postnatal growth retardation J:94589
postnatal lethality, complete penetrance J:94589
small pancreatic islets J:94589
Ins2tm1Delt/Ins2tm1Jja
involves: 129S2/SvPas 		decreased pancreatic beta cell number J:94589
Ins2tm1Jja/Ins2tm1Jja
Tg(Ins2*Y16A)3Ell/0
NOD.Cg-Ins2tm1Jja Tg(Ins2*Y16A)3Ell 		autoimmune response J:98583
increased anti-insulin autoantibody level J:98583
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/16/2024
MGI 6.23 		The Jackson Laboratory